<VariationArchive VariationID="2675489" VariationName="NM_033084.6(FANCD2):c.2609_2613del" VariationType="Deletion" Accession="VCV002675489" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-29" DateCreated="2023-12-30" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2837750" VariationID="2675489">
      <GeneList>
        <Gene Symbol="FANCD2" FullName="FA complementation group D2" GeneID="2177" HGNC_ID="HGNC:3585" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10026437" stop="10101932" display_start="10026437" display_stop="10101932" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10068112" stop="10143613" display_start="10068112" display_stop="10143613" Strand="+" />
          </Location>
          <OMIM>613984</OMIM>
        </Gene>
        <Gene Symbol="LOC107303338" FullName="3p25 FANCD2 Alu-mediated recombination region" GeneID="107303338" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10030947" stop="10078653" display_start="10030947" display_stop="10078653" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_033084.6(FANCD2):c.2609_2613del</Name>
      <CanonicalSPDI>NC_000003.12:10073251:GAAAGGAAA:GAAA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10073252" stop="10073256" display_start="10073252" display_stop="10073256" variantLength="5" positionVCF="10073251" referenceAlleleVCF="AGAAAG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10114936" stop="10114940" display_start="10114936" display_stop="10114940" variantLength="5" positionVCF="10114935" referenceAlleleVCF="AGAAAG" alternateAlleleVCF="A" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_033084.6" sequenceAccession="NM_033084" sequenceVersion="6" change="c.2609_2613del">
            <Expression>NM_033084.6:c.2609_2613del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10114940_10114944del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10114940_10114944del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.10073256_10073260del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.10073256_10073260del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007311.1" sequenceAccession="NG_007311" sequenceVersion="1" change="g.51828_51832del">
            <Expression>NG_007311.1:g.51828_51832del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046754.1" sequenceAccession="NG_046754" sequenceVersion="1" change="g.42410_42414del">
            <Expression>NG_046754.1:g.42410_42414del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_306" sequenceAccession="LRG_306">
            <Expression>LRG_306:g.51828_51832del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_033084.6(FANCD2):c.2609_2613del AND Fanconi anemia complementation group D2" Accession="RCV003460192" Version="1">
        <ClassifiedConditionList TraitSetID="3251">
          <ClassifiedCondition DB="MedGen" ID="C3160738">Fanconi anemia complementation group D2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-27" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_033084.6(FANCD2):c.2609_2613del AND Fanconi anemia" Accession="RCV003779027" Version="1">
        <ClassifiedConditionList TraitSetID="6447">
          <ClassifiedCondition DB="MedGen" ID="C0015625">Fanconi anemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-11-14" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2023-12-30" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17436244</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-25">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3251" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10926" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">FANCONI PANCYTOPENIA, TYPE 4</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">FANCONI ANEMIA, COMPLEMENTATION GROUP D</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group D2</ElementValue>
                <XRef ID="MONDO:0009214" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FA4</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FANCD</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FANCD2</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FACD</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FAD2</ElementValue>
                <XRef Type="MIM" ID="227646" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15169" />
                <XRef ID="15169" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3160738" DB="MedGen" />
              <XRef ID="MONDO:0009214" DB="MONDO" />
              <XRef Type="MIM" ID="227646" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6447" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1797" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia</ElementValue>
                <XRef ID="MONDO:0019391" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
                <XRef ID="84" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi pancytopenia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fanconi's anemia</ElementValue>
                <XRef ID="Fanconi+Anemia/2780" DB="Genetic Alliance" />
                <XRef ID="30575002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FA</ElementValue>
                <XRef Type="MIM" ID="227650" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6425" />
                <XRef ID="6425" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C0015625" DB="MedGen" />
              <XRef ID="D005199" DB="MeSH" />
              <XRef ID="MONDO:0019391" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS227650" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7842590" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_033084.6:c.2609_2613del|OMIM:227646" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004196724" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_033084.6:c.2609_2613del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="227646" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8587940" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="12715554|MedGen:C0015625" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004632167" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17436244</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Arg870Thrfs*12) in the FANCD2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCD2 are known to be pathogenic (PMID: 17436244). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FANCD2-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FANCD2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.10114936_10114940del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0015625" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7842590" TraitType="Disease" MappingType="XRef" MappingValue="227646" MappingRef="OMIM">
        <MedGen CUI="C3160738" Name="Fanconi anemia complementation group D2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8587940" TraitType="Disease" MappingType="XRef" MappingValue="C0015625" MappingRef="MedGen">
        <MedGen CUI="C0015625" Name="Fanconi anemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

